Literature DB >> 29047392

Correction to: Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.

Oliver Schnell1, Eberhard Standl2, Doina Catrinoiu3, Stefano Genovese4, Nebojsa Lalic5, Jan Skra6, Paul Valensi7, Dario Rahelic8, Antonio Ceriello9,10.   

Abstract

Following publication of the original article [1], author Antonio Ceriello requested that a correction be published in relation to his affiliations. His correct affiliations have been updated in this erratum. This correction is very important for the correct assignment of funds to his Institutions.

Entities:  

Year:  2017        PMID： 29047392      PMCID： PMC5645923          DOI： 10.1186/s12933-017-0616-5

Source DB:  PubMed          Journal:  Cardiovasc Diabetol        ISSN： 1475-2840            Impact factor:   9.951


Correction to: Cardiovasc Diabetol (2017) 16:35 DOI 10.1186/s12933-017-0508-8

Following publication of the original article [1], author Antonio Ceriello requested that a correction be published in relation to his affiliations. His correct affiliations have been updated in this erratum. This correction is very important for the correct assignment of funds to his Institutions.
  1 in total

1.  Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.

Authors:  Oliver Schnell; Eberhard Standl; Doina Catrinoiu; Stefano Genovese; Nebojsa Lalic; Jan Skra; Paul Valensi; Dario Rahelic; Antonio Ceriello
Journal:  Cardiovasc Diabetol       Date:  2017-03-11       Impact factor: 9.951
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.